SEND NEWS ARTICLE TO FRIEND
To Email:
From Email:
News Headline
BioCardia and Juventas Therapeutics, Inc. Announce Phase II Development Program of JVS-100 Delivered With the Helical Infusion System to Treat Heart Failure